The Cigna Group (CI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Apr, 2026Opening remarks and agenda
The meeting was opened by the Chair and CEO, with the Board of Directors and Enterprise Leadership Team present.
The agenda and rules of conduct were posted on the meeting website, and participants were asked to abide by them.
Financial performance review
Full-year total revenue for 2025 reached $275 billion, up 11% year-over-year.
Shareholders' net income was $6 billion ($22.18 per share), and adjusted income from operations was $8 billion ($29.84 per share).
Cash flow from operations totaled $9.8 billion, with $5.2 billion returned to shareholders via dividends and share repurchases.
A $3.5 billion investment in Shields Health Solutions and the $4.9 billion sale of the Medicare business were completed in 2025.
Board and executive committee updates
The CEO announced his retirement effective July 1, transitioning to Executive Chair, with the current President and COO succeeding as CEO.
Latest events from The Cigna Group
- Q1 2026 saw higher revenues, profits, and a raised outlook, driven by strong segment results.CI
Q1 20269 May 2026 - Board recommends approval of all annual meeting items except the written consent proposal.CI
Proxy Filing13 Mar 2026 - Strong 2025 results, portfolio focus, and leadership transition headline this year’s proxy.CI
Proxy Filing13 Mar 2026 - Rebate-free PBM model and specialty pharmacy expansion drive growth and transparency.CI
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2025 revenue up 11% to $275B; 2026 EPS guidance at least $30.25, FTC settlement resolved.CI
Q4 20255 Feb 2026 - Q2 revenue up 25%, adjusted EPS up 10%, and $3.7B Medicare sale expected in Q1 2025.CI
Q2 20242 Feb 2026 - EPS guidance reaffirmed, share repurchases prioritized, and specialty pharmacy drives growth.CI
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Growth in specialty, pharmacy, and benefits segments drives innovation and strong financial outlook.CI
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Specialty drug growth and biosimilars drive market leadership and significant client savings.CI
Bernstein Healthcare 1:1 Forum 202420 Jan 2026